Welcome to our dedicated page for REGEN BIOPHARMA news (Ticker: RGBP), a resource for investors and traders seeking the latest updates and insights on REGEN BIOPHARMA stock.
Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) is a pioneering biotechnology company based in La Mesa, California, specializing in the development of small molecule therapies for the treatment of cancer and autoimmune disorders. Founded in 2012, the company focuses on innovative immunology and immunotherapy solutions, rapidly advancing novel technologies from pre-clinical stages through Phase I and II clinical trials.
At the core of Regen BioPharma's research is the NR2F6 small molecule activator, which plays a crucial role in immune cell modulation for oncology and autoimmune diseases. The company's pipeline includes mRNA and small molecule therapies aimed at providing groundbreaking treatments for these debilitating conditions.
Regen BioPharma's recent achievements include significant progress in validating its DuraCAR CAR-T cell therapeutic, designed to target CD19 and NR2F6. Initial in vitro experiments have shown promising results, with subsequent studies revealing unexpected outcomes that could pave the way for developing new autoimmune-suppressive T cell therapies. The company has engaged independent Contract Research Organizations (CROs) to verify these findings, ensuring robust and reproducible data.
The company's commitment to advancing its research is further demonstrated by its ongoing efforts in the autoimmune therapeutic category. Regen BioPharma is poised to initiate a Phase I clinical trial, leveraging its deep intellectual property portfolio and novel technologies.
Regen BioPharma's strategy extends to partnerships and collaborations with leading scientific experts and institutions. This approach not only accelerates the development of their therapies but also positions the company as a significant player in the biotech industry.
For more information, visit Regen BioPharma, Inc.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on September 25, 2024, at 4:00 PM Eastern Time. The company, which focuses on developing cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs, invites investors, advisors, and analysts to attend this interactive online event.
CEO Dr. David Koos will lead the presentation, providing updates on fiscal and scientific goals, progress on current programs, and the timeline for the anticipated HemaXellerate clinical phase I. Attendees will have the opportunity to ask questions in real-time during the 10-minute presentation.
Interested parties can register for the event through the provided link. An archived webcast will be available on EmergingGrowth.com for those unable to attend live.
Regen BioPharma, Inc. is set to present at the Emerging Growth Conference on May 9, 2024, offering shareholders and investors insights into its Phase 1 clinical study-ready HemaXellerate and preclinical DuraCAR programs. The event aims to provide real-time interaction with the CEO, Dr. David Koos, enabling attendees to ask questions and stay updated on the company's advancements in biotechnology.
FAQ
What is the current stock price of REGEN BIOPHARMA (RGBP)?
What is the market cap of REGEN BIOPHARMA (RGBP)?
What is Regen BioPharma, Inc.?
What is the NR2F6 small molecule?
Where is Regen BioPharma, Inc. based?
When was Regen BioPharma, Inc. founded?
What are the recent achievements of Regen BioPharma?
What is the focus of Regen BioPharma's current projects?
Who is the CEO of Regen BioPharma, Inc.?
What is the significance of the DuraCAR CAR-T cell therapeutic?
How does Regen BioPharma ensure the validity of its research?
How can I get more information about Regen BioPharma, Inc.?
